{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:31:30Z","timestamp":1740130290870,"version":"3.37.3"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:00:00Z","timestamp":1609286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>BRCA1\/2 mutation carriers are at high risk for type II ovarian, fallopian tube or peritoneal cancer. Although risk-reducing salpingo-oophorectomy plays an important role in the prevention of these BRCA1\/2-associated gynecological cancers, occult ovarian, fallopian tube, or peritoneal cancer is discovered upon risk-reducing salpingo-oophorectomy in 1\u20134% of BRCA1\/2 mutation carriers. Notably, around 30% of BRCA1\/2 mutation carriers who undergo risk-reducing salpingo-oophorectomy have undergone adjuvant chemotherapy for breast cancer. We describe the discovery and treatment of occult cancer at the edge of the left fimbria in a BRCA1 mutation carrier who had, just a short time previously, undergone neoadjuvant paclitaxel plus carboplatin (TC) chemotherapy for triple-negative breast cancer. During subsequent risk-reducing salpingo-oophorectomy, a 5.5-mm nodule was observed at the edge of the left fimbria. Microscopic examination of the tumour tissue revealed high-grade serous carcinoma with degenerate tumour cells and fibrosis. Peritoneal fluid was negative for cancer cells. Two months later, hysterectomy, omentectomy and retroperitoneal lymphadenectomy were performed. The final diagnosis was stage FIGO IA fallopian tube cancer. Adjuvant chemotherapy (TC administered every 3\u00a0weeks) was applied, and there has been no evidence of recurrence for 5\u00a0years. In applying gynecologic surgery and adjuvant chemotherapy, we followed the general recommendation for stage IA fallopian tube cancer. There is no standard strategy for the treatment of occult fallopian tube cancer detected after chemotherapy for BRCA1-associated triple-negative breast cancer. According to our experience in this case, we believe the clinical value of staging laparotomy in cases of a small occult BRCA1\/2-associated gynecological cancer should be further investigated.<\/jats:p>","DOI":"10.1093\/jjco\/hyaa239","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T12:17:14Z","timestamp":1605529034000},"page":"492-497","source":"Crossref","is-referenced-by-count":0,"title":["Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for <i>BRCA1\/2<\/i>-associated breast cancer: a case report"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9714-7476","authenticated-orcid":false,"given":"Shiho","family":"Kuji","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiro","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuru","family":"Ohara","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imari","family":"Deura","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Tozawa-Ono","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ohsuke","family":"Migita","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, St. Marianna University School of Medicine, Kawasaki-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisanori","family":"Kawamoto","sequence":"additional","affiliation":[{"name":"Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine, Kawasaki-shi, Japan"},{"name":"St. Marianna University Breast & Imaging Center, Kawasaki-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Tsugawa","sequence":"additional","affiliation":[{"name":"Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine, Kawasaki-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Chosokabe","sequence":"additional","affiliation":[{"name":"Department of Pathology, St. Marianna University School of Medicine, Kawasaki-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junki","family":"Koike","sequence":"additional","affiliation":[{"name":"Department of Pathology, St. Marianna University School of Medicine, Kawasaki-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Kitasato University Kitasato Institute Hospital, Tokyo Japan"},{"name":"Department of Pathology, Kitasato University School of Medicine, Sagamihara-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki-shi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,30]]},"reference":[{"key":"2021030800240835100_ref1","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"2021030800240835100_ref2","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"2021030800240835100_ref3","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J Clin Oncol"},{"volume-title":"Surveillance, Epidemiology, and End Results (SEER) Program","author":"National Cancer Institute","key":"2021030800240835100_ref4"},{"key":"2021030800240835100_ref5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am J Pathol"},{"key":"2021030800240835100_ref6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/pgp.0b013e31814b191f","article-title":"Serous carcinogenesis in the fallopian tube: a descriptive classification","volume":"27","author":"Jarboe","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"2021030800240835100_ref7","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2014shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Hum Pathol"},{"key":"2021030800240835100_ref8","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/PAS.0b013e318282da7f","article-title":"Fallopian tube intraluminal tumor spread from noninvasive precursor lesions a novel metastatic route in early pelvic carcinogenesis","volume":"37","author":"Bijron","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"2021030800240835100_ref9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ygyno.2016.08.336","article-title":"Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers","volume":"143","author":"Zakhour","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2021030800240835100_ref10","first-page":"689","volume-title":"AJCC Cancer Staging Manual. Eighth Edition (English Edition)","author":"Mutch","year":"2018"},{"volume-title":"Protocols and guidelines protocol for the examination of specimens from patients with primary tumors of the ovary, fallopian tube, or peritoneum. Version 1.1.1.0","year":"2020","author":"College of American Pathologists","key":"2021030800240835100_ref11"},{"volume-title":"Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Ver 1","year":"2020","author":"NCCN Clinical Practice Guidelines in Oncology","key":"2021030800240835100_ref12"},{"key":"2021030800240835100_ref13","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1200\/JCO.2013.54.1987","article-title":"Pathologic findings at risk-reducing salpingo-oophorectomy: primary result from Gynecologic oncology group trial GOG-0199","volume":"32","author":"Sherman","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021030800240835100_ref14","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s10147-019-01456-4","article-title":"Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan","volume":"24","author":"Nomura","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"2021030800240835100_ref15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s10038-017-0355-1","article-title":"Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan","volume":"63","author":"Arai","year":"2018","journal-title":"J Hum Genet"},{"key":"2021030800240835100_ref16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021030800240835100_ref17","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","article-title":"De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017","volume":"28","author":"Curigliano","year":"2017","journal-title":"Ann Oncol"},{"key":"2021030800240835100_ref18","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2021030800240835100_ref19","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N Engl J Med"},{"key":"2021030800240835100_ref20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic oncology group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021030800240835100_ref21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"2021030800240835100_ref22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2005.04.109","article-title":"Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy","volume":"23","author":"Powell","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021030800240835100_ref23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"key":"2021030800240835100_ref24","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021030800240835100_ref25","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/cncr.22603","article-title":"This P, et\u00a0al. prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation","volume":"109","author":"Laki","year":"2007","journal-title":"Cancer"},{"key":"2021030800240835100_ref26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/01.AOG.0000228959.30577.13","article-title":"Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations","volume":"108","author":"Schmeler","year":"2006","journal-title":"Obstet Gynecol"},{"key":"2021030800240835100_ref27","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/978-3-319-46334-6_11","volume-title":"Blaustein\u2019s Pathology of the Female Genital Tract","author":"Vang","year":"2019","edition":"7th"},{"key":"2021030800240835100_ref28","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ygyno.2020.02.006","article-title":"Pathologic findings and clinical outcomes in women undergoing risk reducing surgery to prevent ovarian and fallopian tube carcinoma: a large prospective single institution experience","volume":"157","author":"Rush","year":"2020","journal-title":"Gynecol Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/3\/492\/36446315\/hyaa239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/3\/492\/36446315\/hyaa239.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:24:31Z","timestamp":1615163071000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/51\/3\/492\/6055141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,30]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,12,30]]},"published-print":{"date-parts":[[2021,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa239","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2020,12,30]]}}}